Featured Research

from universities, journals, and other organizations

Trio of studies support use of PET/CT scans as prostate cancer staging tool

Date:
October 21, 2011
Source:
Mayo Clinic
Summary:
Recent studies have suggested that C-11 choline positron emission tomography/computerized tomography scans can be utilized as a staging and potentially therapeutic tool in prostate cancer.

Recent studies have suggested that C-11 choline positron emission tomography/computerized tomography (PET/CT) scans can be utilized as a staging and potentially therapeutic tool in prostate cancer. The results of three studies, released during a meeting of the North Central Section of the American Urological Association, validate findings in Europe and expand the potential use of C-11 choline PET scans.

One study found that C-11 choline PET/CT scans can be used as a staging tool rather than multiple x-rays, but is not necessarily better. Two additional studies support the favorable claims made in recent medical literature about the use of PET scans to evaluate patients with recurrent prostate cancer. These findings are important because distinguishing localized disease recurrence from systemic recurrence is a vital step in optimizing treatment following primary treatment failure.

"Taken together, the three studies presented today represent an important validation of the C-11 choline PET/CT scan as a staging tool for patients with prostate cancer," says R. Jeffrey Karnes, M.D., senior author of all three papers. "We believe the use of these scans can improve the staging and treatment of this common form of cancer, while potentially reducing the cost of delivering the best possible care."

Positron emission tomography is an imaging test that uses a small amount of radioactive material to reveal how tissues and organs are functioning. A C-11 choline PET scan involves the injection into a vein of a small amount of C-11 choline, a radioactive form of the vitamin choline. Clinicians then use a scanner and computer to make detailed pictures of areas where the C-11 choline collects. Since cancer cells take up more C-11 choline than normal cells, the pictures can be used to find cancer in the body.

Summary of the Three Studies

  • "Initial Staging for High-Risk Prostate Cancer: Is there a Role for C-11 Choline PET Scan?" -- The findings suggest that C11-choline PET is an accurate diagnostic tool when used as the initial staging modality prior to definitive treatment and could potentially eliminate the need for CT and/or bone scans.
  • "Detection of Consolidated Disease Recurrences of Prostate Cancer by C-11 Choline PET Scan: Results Confirmed by Surgical Resection" -- This study found that a C-11 choline PET scan is an accurate diagnostic tool for detecting localized disease recurrences that, in select cases, are suitable for salvage surgical resection.
  • "Operational Characteristics of C-11 Choline PET Scan for Prostate Cancer Patients with Biochemical Recurrence Following Initial Treatment" -- The operational performance of C11-choline PET for evaluating patients with recurrent prostate cancer supports the favorable claims regarding this technology. The use of C-11-choline PET substantially enhances the rate of prostate cancer lesion detection by approximately 30% beyond what can be garnered using conventional imaging technologies.

About Prostate Cancer

According to the American Cancer Society, prostate cancer affects approximately one in six American men, and is the second most common cancer among this patient group, behind skin cancer. While death from prostate cancer is the second-leading cause of cancer death in American men, and more than 240,000 men will be diagnosed with the disease this year, it is treatable. More than 2 million prostate cancer survivors live in the United States today.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Trio of studies support use of PET/CT scans as prostate cancer staging tool." ScienceDaily. ScienceDaily, 21 October 2011. <www.sciencedaily.com/releases/2011/10/111021162253.htm>.
Mayo Clinic. (2011, October 21). Trio of studies support use of PET/CT scans as prostate cancer staging tool. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/10/111021162253.htm
Mayo Clinic. "Trio of studies support use of PET/CT scans as prostate cancer staging tool." ScienceDaily. www.sciencedaily.com/releases/2011/10/111021162253.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins